Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
Molecular Research on the Pancreatic Cancer
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Molecular Research on the Pancreatic Cancer

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 20 June 2025 | Viewed by 7825

Special Issue Editors

Dr. Tetsufumi Takahashi

E-Mail Website
Guest Editor
Department of Kampo Pharmacy, Yokohama University of Pharmacy, Yokohama, Japan
Interests: pancreatic cancer; exosome; cancer stem cell; 3D culture; cancer-associated fibroblasts
Dr. Akira Sato

E-Mail Website
Guest Editor
Department of Biochemistry & Molecular Biology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan
Interests: cell death; anticancer drug resistance; cancer prevention & treatment; non-coding RNA
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, is a highly lethal human malignancy, with a conspicuously subdued 5-year overall survival rate. Many PDAC patients are diagnosed at an advanced stage, thereby frequently developing metastasis. A compendium of prospective PDAC biomarkers has been elucidated; however, their definitive validation remains pending. Multiple alterations at the molecular and cellular level, including nucleotide metabolism enzymes, apoptosis pathway, drug efflux pumps, cancer stem cells or epithelial-to-mesenchymal transition (EMT) pathway, have the capacity to influence the chemoresistant nature of PDAC. Furthermore, PDAC exhibits an extensive desmoplastic reaction, characterized by abundant extracellular matrix components, inflammatory cells, and cancer-associated fibroblasts (CAFs). It is suggested that the interplay between pancreatic cancer cells and tumor-associated cells, such as CAFs or tumor-associated macrophages (TAMs), governs the metastatic proclivity and chemoresistant propensities of PDAC. Additionally, exosomal miRNA has garnered attention as a potential biomolecular marker and pathological modulator in PDAC.

So, this special issue focuses on the diagnosis, pathology, and treatment of PDAC, and will includes papers on (1) evaluation of potential biomarker, (2) mechanisms of metastasis, (3) chemoresistance of PDAC.

Dr. Tetsufumi Takahashi
Dr. Akira Sato
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • PDAC
  • biomarker
  • metastasis
  • chemoresistance

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

19 pages, 1942 KiB  
Review
Sex-Related Differences in Pancreatic Ductal Adenocarcinoma Progression and Response to Therapy
by Jelena Grahovac, Ana Đurić, Miljana Tanić and Ana Krivokuća
Int. J. Mol. Sci. 2024, 25(23), 12669; https://doi.org/10.3390/ijms252312669 - 26 Nov 2024
Viewed by 1478
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most deadly malignancies with an increasing incidence rate and limited therapeutic options. Biological sex has an impact on many aspects of PDAC development and response to therapy, yet it is highly unappreciated in both basic [...] Read more.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most deadly malignancies with an increasing incidence rate and limited therapeutic options. Biological sex has an impact on many aspects of PDAC development and response to therapy, yet it is highly unappreciated in both basic and translational research, and worryingly in PDAC clinical trials. In this review, we summarize how biological sex influences PDAC incidence and mortality, genetic and epigenetic landscapes, anti-tumor immunity, responses to hormones, cachexia, and the efficacy of therapy. We highlight the importance of sex as a variable and discuss how to implement it into preclinical and clinical research. These considerations should be of use to researchers aiming at improving understanding of PDAC biology and developing precision medicine therapeutic strategies. Full article
(This article belongs to the Special Issue Molecular Research on the Pancreatic Cancer)
►▼ Show Figures

Figure 1

25 pages, 922 KiB  
Review
Advancing Immunotherapy in Pancreatic Cancer
by Ahmad Hegazi, Lauren Elizabeth Rager, Dean Edward Watkins and Kuo-Hui Su
Int. J. Mol. Sci. 2024, 25(21), 11560; https://doi.org/10.3390/ijms252111560 - 28 Oct 2024
Cited by 2 | Viewed by 2614
Abstract
Pancreatic cancer remains one of the deadliest malignancies, with a consistently low five-year survival rate for the past several decades. This is in stark contrast to other cancers, which have seen significant improvement in survival and prognosis due to recent developments in therapeutic [...] Read more.
Pancreatic cancer remains one of the deadliest malignancies, with a consistently low five-year survival rate for the past several decades. This is in stark contrast to other cancers, which have seen significant improvement in survival and prognosis due to recent developments in therapeutic modalities. These modest improvements in pancreatic cancer outcomes have primarily resulted from minor advances in cytotoxic chemotherapeutics, with limited progress in other treatment approaches. A major focus of current therapeutic research is the further development of immunomodulatory therapies characterized by antibody-based approaches, cellular therapies, and vaccines. Although initial results utilizing immunotherapy in pancreatic cancer have been mixed, recent clinical trials have demonstrated significant improvements in patient outcomes. In this review, we detail these three approaches to immunomodulation, highlighting their common targets and distinct shortcomings, and we provide a narrative summary of completed and ongoing clinical trials that utilize these approaches to immunomodulation. Within this context, we aim to inform future research efforts by identifying promising areas that warrant further exploration. Full article
(This article belongs to the Special Issue Molecular Research on the Pancreatic Cancer)
►▼ Show Figures

Figure 1

25 pages, 744 KiB  
Review
Understanding the Conundrum of Pancreatic Cancer in the Omics Sciences Era
by Alberto Nicoletti, Mattia Paratore, Federica Vitale, Marcantonio Negri, Giuseppe Quero, Giorgio Esposto, Irene Mignini, Sergio Alfieri, Antonio Gasbarrini, Maria Assunta Zocco and Lorenzo Zileri Dal Verme
Int. J. Mol. Sci. 2024, 25(14), 7623; https://doi.org/10.3390/ijms25147623 - 11 Jul 2024
Cited by 3 | Viewed by 2401
Abstract
Pancreatic cancer (PC) is an increasing cause of cancer-related death, with a dismal prognosis caused by its aggressive biology, the lack of clinical symptoms in the early phases of the disease, and the inefficacy of treatments. PC is characterized by a complex tumor [...] Read more.
Pancreatic cancer (PC) is an increasing cause of cancer-related death, with a dismal prognosis caused by its aggressive biology, the lack of clinical symptoms in the early phases of the disease, and the inefficacy of treatments. PC is characterized by a complex tumor microenvironment. The interaction of its cellular components plays a crucial role in tumor development and progression, contributing to the alteration of metabolism and cellular hyperproliferation, as well as to metastatic evolution and abnormal tumor-associated immunity. Furthermore, in response to intrinsic oncogenic alterations and the influence of the tumor microenvironment, cancer cells undergo a complex oncogene-directed metabolic reprogramming that includes changes in glucose utilization, lipid and amino acid metabolism, redox balance, and activation of recycling and scavenging pathways. The advent of omics sciences is revolutionizing the comprehension of the pathogenetic conundrum of pancreatic carcinogenesis. In particular, metabolomics and genomics has led to a more precise classification of PC into subtypes that show different biological behaviors and responses to treatments. The identification of molecular targets through the pharmacogenomic approach may help to personalize treatments. Novel specific biomarkers have been discovered using proteomics and metabolomics analyses. Radiomics allows for an earlier diagnosis through the computational analysis of imaging. However, the complexity, high expertise required, and costs of the omics approach are the main limitations for its use in clinical practice at present. In addition, the studies of extracellular vesicles (EVs), the use of organoids, the understanding of host–microbiota interactions, and more recently the advent of artificial intelligence are helping to make further steps towards precision and personalized medicine. This present review summarizes the main evidence for the application of omics sciences to the study of PC and the identification of future perspectives. Full article
(This article belongs to the Special Issue Molecular Research on the Pancreatic Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop